Roka BioScience, Inc.
Funding rounds
4 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Sep 2016 | $23 M | No. 4 | $10 to $50 million | equity, options | SEC | |
| Nov 2013 | $17 M | No. 3 | $10 to $50 million | equity | SEC | |
| Jun 2013 | $25 M | No. 2 | $10 to $50 million | equity, options | SEC | |
| Sep 2009 | $28 M | No. 1 | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Roka BioScience, Inc. chose not to state its revenue in its newest notice of a funding round (Sep 2016).
SEC Form D · Sep 2016
The industry group it chose in its notices: Biotechnology.
SEC Form D · Sep 2016
That is all the official record says: Roka BioScience, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
6 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| NEA 13 GP, Ltd | Company | not stated | not stated | Held Series B, C, D and E preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| NEA Partners 13, Limited Partnership | Fund or asset manager | not stated | not stated | Held Series B, C, D and E preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| New Enterprise Associates 13 LP | Fund or asset manager | not stated | not stated | Held Series B, C, D and E preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Orbimed Advisors LLC | Fund or asset manager | not stated | not stated | Held Series B, C, D and E preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| OrbiMed Capital GP III LLC | Fund or asset manager | not stated | not stated | Held Series B, C, D and E preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| TPG Group Holdings (SBS) Advisors, Inc. | Fund or asset manager | not stated | not stated | Held Series A, B, C, D and E preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 32 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Lars Boesgaard | Executive officer | Sep 2016 |
| Paul G. Thomas | Executive officer | Sep 2016 |
| Paul Thomas | President, Chief Executive Officer and Secretary | Dec 2013 |
| Steven Sobieski | Chief Financial Officer and Treasurer | Dec 2013 |
| Paul T. Thomas | President, Chief Executive Officer and Secretary | May 2011 |
| Steven T. Sobieski | Treasurer and Chief Financial Officer | May 2011 |
| David G. McGirr | Director | Sep 2016 |
| Fred G. Cohen | Director | Sep 2016 |
| Jim G. Barret, PhD | Director | Sep 2016 |
| Jonathan G. Silverstein | Director | Sep 2016 |
| Michael P. Doyle | Director | Sep 2016 |
| Nicholas G. Valeriani | Director | Sep 2016 |
| Paul G. Thomas | Director | Sep 2016 |
| Fred Cohen | Director | Dec 2013 |
| Jim Barret, PhD | Director | Dec 2013 |
| Jonathan Silverstein | Director | Dec 2013 |
| Josh Bilenker, MD | Director | Dec 2013 |
| Paul Thomas | President, Chief Executive Officer and Secretary | Dec 2013 |
| Fred J. Cohen | Director | Jun 2013 |
| Michael J. Watts | Director | Jun 2013 |
| Paul T. Thomas | President, Chief Executive Officer and Secretary | May 2011 |